Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead's Quad Poised To Take Chunk Of Atripla's Market, If Phase III Results Hold Up

This article was originally published in The Pink Sheet Daily

Executive Summary

Solid efficacy with fewer psych effects than Atripla continue in full-length version of Phase II trials. However, hopes for superior performance have started to wane.
Advertisement

Related Content

Gilead Hedges Against Eventual Generic Competition For Atripla With Bristol HIV Pact
Gilead Hedges Against Eventual Generic Competition For Atripla With Bristol HIV Pact
Rilpivirine Label Highlights Risk In Patients With Higher HIV Levels, Could Limit Use
Rilpivirine Label Highlights Risk In Patients With Higher HIV Levels, Could Limit Use
Gilead Files Next HIV Triple-Combo Pill, With Hopes Of Prophylaxis Claim; Can Firm Recreate HIV Success In Hep C?
Gilead's Next HIV Triple-Combo Pill May Prevent Generic Erosion; Can It Prevent Infection Itself?
Tibotec Files Once-Daily NNRTI Rilpivirine, Part Of Gilead's New Combo For HIV
Gilead: Near-Term Drug Filings Planned, But HIV Pressure Persists
Gilead's HIV Quad Pill Passes Tolerability Test, But Not With A Straight "A"
Gilead's HIV Quad Pill Passes Tolerability Test, But Not With A Straight "A"

Topics

Advertisement
UsernamePublicRestriction

Register

PS071167

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel